[11C]5-Hydroxy-tryptophan PET for Assessment of Islet Mass in Type 2 Diabetes
NCT ID: NCT02967354
Last Updated: 2018-01-30
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
39 participants
INTERVENTIONAL
2013-01-31
2015-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
11C-5-HTP PET in Clinical Islet Transplantation
NCT02689479
18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia
NCT01916148
Effect of Gastric Bypass Surgery on Pancreatic Islet and Incretin Function - Follow-up Study
NCT02161666
GLP-1 Receptor Targeting in Diabetic and Healthy Individuals
NCT01825148
Evaluation of the Efficacy of Intramuscular Islet Autograft After Extensive Pancreatectomy
NCT02872571
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy control
Healthy control
Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan
Estimation of islet mass by PET using the tracer \[11C\]5-hydroxy-tryptophan
Obese with oral antidiabetic drugs
BMI\>30, Type 2 diabetes treated with oral antidiabetic drugs
Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan
Estimation of islet mass by PET using the tracer \[11C\]5-hydroxy-tryptophan
Obese, treated with oral antidiabetic drugs + insulin
BMI\>30, Type 2 diabetes treated with oral antidiabetic drugs + insulin
Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan
Estimation of islet mass by PET using the tracer \[11C\]5-hydroxy-tryptophan
Normal weight, treated with oral antidiabetic drugs
BMI 20-26. Type 2 diabetes treated with oral antidiabetic drugs
Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan
Estimation of islet mass by PET using the tracer \[11C\]5-hydroxy-tryptophan
Normal weight, treated with oral antidiabetic drugs + insulin
BMI 20-26. Type 2 diabetes treated with oral antidiabetic drugs + insulin
Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan
Estimation of islet mass by PET using the tracer \[11C\]5-hydroxy-tryptophan
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan
Estimation of islet mass by PET using the tracer \[11C\]5-hydroxy-tryptophan
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Renal failure (GFR\<60 ml/min)
* Magnetic metal parts in the body
* Ongoing treatment with selective serotonin receptor inhibitors
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Per-Ola Carlsson
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Per-Ola Carlsson
Professor, Senior consultant
References
Explore related publications, articles, or registry entries linked to this study.
Carlbom L, Espes D, Lubberink M, Martinell M, Johansson L, Ahlstrom H, Carlsson PO, Korsgren O, Eriksson O. [11C]5-hydroxy-tryptophan PET for Assessment of Islet Mass During Progression of Type 2 Diabetes. Diabetes. 2017 May;66(5):1286-1292. doi: 10.2337/db16-1449. Epub 2017 Feb 28.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Dnr 2012/302
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.